准河马途径作为癌症免疫疗法中免疫检查点的潜在调节者
Yu-Ying Meng1, Xin Chang2, Si-Si Cao1
1Pharmaceutical College, Guangxi Medical University, Nanning 530021, China.
International immunopharmacology
|June 15, 2025
概括
河马通路调节免疫检查点和瘤微环境. 针对这种途径可以通过调节免疫细胞和减少副作用来改善癌症免疫疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 涉及YAP/TAZ和TEAD因子的Hippo通路控制细胞生长和器官大小.
- 河马通路的失调与癌症的进展有关,包括转移.
- 瘤微环境 (TME) 显著影响癌症的发展和治疗反应.
研究的目的:
- 审查Hippo途径在调节免疫检查点 (IC) 中的作用.
- 探索Hippo路径对瘤微环境 (TME) 的影响.
- 讨论针对Hippo途径以增强癌症免疫治疗的潜力.
主要方法:
- 对Hippo路径,免疫检查点和TME的研究进行文献综述.
- 对Hippo通路影响TME内的免疫细胞功能机制的分析.
- 检查Hippo通路对免疫检查点抑制剂 (ICI) 的调节.
主要成果:
- 河马通路调节T细胞功能,骨髓衍生抑制细胞 (MDSC) 活动,以及TME内的巨细胞极化/招募.
- 河马通路信号影响免疫检查点的表达.
- 调节Hippo路径显示了提高免疫疗法疗效的潜力.
结论:
- 河马通路是瘤微环境中的免疫反应的关键调节者.
- 准Hippo通路为增强癌症免疫治疗提供了一个有希望的策略.
- 对Hippo通路调节的进一步研究可能会导致更好的癌症治疗,副作用更少.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
7.0K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
相关概念视频
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
